- Home
- VYGR vs OPP Comparison
VYGR vs OPP Comparison
Compare VYGR & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- OPP
- Stock Information
- Founded
- VYGR 2013
- OPP 2010
- Country
- VYGR United States
- OPP United States
- Employees
- VYGR N/A
- OPP N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- OPP Finance/Investors Services
- Sector
- VYGR Health Care
- OPP Finance
- Exchange
- VYGR Nasdaq
- OPP Nasdaq
- Market Cap
- VYGR 235.4M
- OPP 204.1M
- IPO Year
- VYGR 2015
- OPP N/A
- Fundamental
- Price
- VYGR $4.22
- OPP $8.54
- Analyst Decision
- VYGR Strong Buy
- OPP
- Analyst Count
- VYGR 9
- OPP 0
- Target Price
- VYGR $15.53
- OPP N/A
- AVG Volume (30 Days)
- VYGR 374.5K
- OPP 108.0K
- Earning Date
- VYGR 03-03-2025
- OPP 01-01-0001
- Dividend Yield
- VYGR N/A
- OPP 14.41%
- EPS Growth
- VYGR N/A
- OPP N/A
- EPS
- VYGR 0.47
- OPP N/A
- Revenue
- VYGR $163,784,000.00
- OPP N/A
- Revenue This Year
- VYGR N/A
- OPP N/A
- Revenue Next Year
- VYGR N/A
- OPP N/A
- P/E Ratio
- VYGR $9.13
- OPP N/A
- Revenue Growth
- VYGR 3.40
- OPP N/A
- 52 Week Low
- VYGR $4.00
- OPP $7.26
- 52 Week High
- VYGR $10.66
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- VYGR 29.98
- OPP 50.73
- Support Level
- VYGR $4.20
- OPP $8.53
- Resistance Level
- VYGR $4.60
- OPP $8.77
- Average True Range (ATR)
- VYGR 0.31
- OPP 0.07
- MACD
- VYGR -0.08
- OPP -0.01
- Stochastic Oscillator
- VYGR 12.36
- OPP 17.86
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.